Peter Glazer

Professor and Chair

Yale University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Year:

2026

Stimulator of IFN genes (STING), a key component of the cyclic GMP-AMP synthase/STING pathway, is crucial for nucleic acid sensing and plays a significant role in tumor immune responses. However, STING is often silenced in various cancers, aiding tumor development. This study showed that tumor hypoxia downregulates STING in multiple cancer types, suppressing downstream pathways and inhibiting immunogenic cell death. Hypoxia-induced downregulation of STING occurred in a HIF1α–dependent manner, and STING silencing was associated with epigenetic modifications mediated by lysine demethylases KDM1A and KDM5A, further exacerbated by oncometabolite dysregulation. In vivo , hypoxia affected the efficacy of STING agonists on tumor growth and immune responses. Inhibiting KDM1A reversed hypoxia-induced STING downregulation and reactivated STING in previously suppressed cancer cells. This study highlights the interaction between hypoxia, oncometabolites, and immune signaling in cancer and suggests that targeting KDM1A could restore the STING pathway and improve the efficacy of cancer therapy. Significance: Hypoxia silences STING expression in a HIF1α–dependent manner that is mediated by KDM1A/KDM5A and oncometabolites, which can be reversed by targeting KDM1A as a potential strategy for enhancing cancer therapy responses.

Year:

2025

Stimulator of IFN genes (STING), a key component of the cyclic GMP-AMP synthase/STING pathway, is crucial for nucleic acid sensing and plays a significant role in tumor immune responses. However, STING is often silenced in various cancers, aiding tumor development. This study showed that tumor hypoxia downregulates STING in multiple cancer types, suppressing downstream pathways and inhibiting immunogenic cell death. Hypoxia-induced downregulation of STING occurred in a HIF1α–dependent manner, and STING silencing was associated with epigenetic modifications mediated by lysine demethylases KDM1A and KDM5A, further exacerbated by oncometabolite dysregulation. In vivo, hypoxia affected the efficacy of STING agonists on tumor growth and immune responses. Inhibiting KDM1A reversed hypoxia-induced STING downregulation and reactivated STING in previously suppressed cancer cells. This study highlights the interaction between hypoxia, oncometabolites, and immune signaling in cancer and suggests that targeting KDM1A could restore the STING pathway and improve the efficacy of cancer therapy. Significance: Hypoxia silences STING expression in a HIF1α–dependent manner that is mediated by KDM1A/KDM5A and oncometabolites, which can be reversed by targeting KDM1A as a potential strategy for enhancing cancer therapy responses.

Year:

2025

Luminex cytokine profiling of serum obtained from OT1 mice treated with pHLIP-SIINFEKL or controls. Blood was harvested after three treatments and analyzed for the indicated cytokine levels ( n =3).

Year:

2025

Knockdown of β2m abrogates OT1 T cell engagement with pHLIP-SIINFEKL-treated B16-F10 cells. A, Western blot showing siRNA knockdown of β2m or GAPDH (control) in B16-F10 cells with Vinculin loading control. B, B16-F10 cells were treated with siRNA to β2m or to GAPDH followed by treatment with pHLIP-SIINFEKL or pHLIP-NULL (1uM) for 2 hours. The cells were then co-cultured with fluorescently labeled OT1 T cells for an additional two hours. Cell cultures were washed to remove unbound OT1 T cells that had not engaged with the B16-F10 cells, followed by fluorescence microscopy. C, Quantification of OT1 T cell/total cell number showing a significant reduction in OT1 engagement in the pHLIP-SIINFEKL + OT1 treatment group when the B16-F10 cells were pre-treated with β2m siRNA compared to GAPDH siRNA control. Statistical analyses by unpaired two-tailed T -test, with p-value shown.

Year:

2025

B16 OVA tumor growth in C57BL/6 mice versus OT1 mice. A, Tumor growth curves of B16 OVA melanoma tumors in C57BL/6 mice or OT1 mice, as indicated. Statistical comparisons by two-way RM-ANOVA. B, Survival curves from (A). Statistical comparisons by Log-rank (Mantel–Cox) test, n =4 mice per group.

Year:

2025

Treatment with SIINFEKL alone in vivo does not impact tumor growth. A, Tumor growth curves of B16-F10 melanoma tumors in OT1 mice, treated with SIINFEKL or untreated as indicated. Statistical comparisons by two-way RM-ANOVA. B, Survival curves from (A). Statistical comparisons by Log-rank (Mantel–Cox) test, n =8 mice per group.

Year:

2025

Cysteine addition to SIINFEKL does not impact T cell recognition, but S to E substitution abrogates recognition. Assay for engagement of OT1 T cells with B16-F10 melanoma cells electroporated with SIINFEKL-related peptides. Peptides were electroporated into B16-F10 cells which were subsequently co-cultured with far-red fluorescently dyed OT1 T cells at a 10:1 effector:target cell ratio for 2 h, followed by washing and visualization by fluorescent microscopy. B16-F10 cells were stained by DAPI. Peptides tested were the parental SIINFEKL (the naturally occurring sequence from ovalbumin), CSIINFEKL which contains the addition of an N-terminal cysteine, EIINFEKL, which has glutamic acid (E) substituted for serine (S), and CEIINFEKL with both an Nterminal cysteine and a glutamic acid substitution for serine.

Year:

2025

Identifying an optimal antigen for targeted cancer therapy is challenging as the antigen landscape on cancerous tissues mimics that of healthy tissues, with few unique tumor-specific antigens identified in individual patients. pH low insertion peptide (pHLIP) acts as a unique delivery platform that can specifically target the acidic microenvironment of tumors, sparing healthy tissue in the process. We developed a pHLIP-peptide conjugate to deliver the SIINFEKL peptide, an immunogenic fragment of ovalbumin (OVA), to tumor cells in vivo . When processed intracellularly, SIINFEKL is presented for immune recognition through the major histocompatibility complex (MHC) class I pathway. We observed selective delivery of pHLIP-SIINFEKL both in vitro and in vivo using fluorescently labeled constructs. In vitro , treatment of melanoma tumor cells with pHLIP-SIINFEKL resulted in recognition by SIINFEKL-specific T cells (OT1), leading to T-cell activation and effector function. Mechanistically, we show that this recognition by OT1 T cells was abrogated by siRNA/shRNA knockdown of multiple components within the MHC class I pathway in the target tumor cells, indicating that an intact antigen processing pathway in the cancer cells is necessary to mediate the effect of pHLIP-directed SIINFEKL delivery. In vivo , pHLIP-SIINFEKL treatment of tumor-bearing mice resulted in the recruitment of OT1 T cells and suppression of tumor growth in two syngeneic tumor models in immunocompetent mice, with no effect when mutating either the pHLIP or SIINFEKL components of the conjugate. These results suggest that pHLIP-mediated peptide delivery can be used to deliver novel artificial antigens that can be targeted by cell-based therapies.

Year:

2025

In utero gene editing has the potential to modify disease causing genes in multiple developing tissues before birth, possibly allowing for normal organ development, disease improvement, and conceivably, cure. In cystic fibrosis (CF), a disease that arises from mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene, there are signs of multiorgan disease affecting the function of the respiratory, gastrointestinal, and reproductive systems already present at birth. Thus, treating CF patients early is crucial for preventing or delaying irreversible organ damage. Here we demonstrate proof-of-concept of multiorgan mutation correction in CF using peptide nucleic acids (PNAs) encapsulated in polymeric nanoparticles and delivered systemically in utero. In utero editing was associated with sustained postnatal CFTR activity, at a level similar to that of wild-type mice, in both respiratory and gastrointestinal tissue, without detection of off-target mutations in partially homologous loci. This work suggests that systemic in utero gene editing represents a viable strategy for treating monogenic diseases before birth that impact multiple tissue types.

Year:

2024

Collaborators (9)

Marie Egan

Professor

Yale University

UNITED STATES
View details

W. Mark Saltzman

Professor

Yale University

UNITED STATES
View details

Samuel Katz

Yale University

UNITED STATES
View details

Caroline Zeiss

Yale University School of Medicine

UNITED STATES
View details

Martin Mueller

Voluntary Associate Professor

Inselspital Universitätsspital Bern

SWITZERLAND
View details

Arumugam R. Jayakumar

University of Miami Miller School of Medicine

UNITED STATES
View details

Anisha Gupta

Assistant Professor

University of Saint Joseph School of Pharmacy

UNITED STATES
View details

Alexandra Piotrowski-Daspit

Assistant Professor

University of Michigan

UNITED STATES
View details

Daniel Zelterman

Professor

Yale School of Public Health

UNITED STATES
View details